UVEAL MELANOMA

This phase II trial tests two drugs—olaparib and pembrolizumab—together in 12 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal is to see if the combination can shrink tumors or slow the disease. The study is active but no longer recruiting, and res…

This early-phase trial tests a radioactive drug called 225Ac-MTI-201 in 16 people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. The main goal is to find the highest safe dose and understand side effects. Participants receive a singl…

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also chec…

This study tests a treatment that uses a patient's own immune cells (T-cells) to fight advanced melanoma. Some participants also receive a dendritic cell vaccine to boost the immune response. The goal is to see if the T-cells last longer and work better against the cancer. The tr…

This phase 2 trial tests darovasertib, a daily pill, in 160 people with uveal melanoma (a rare eye cancer). The drug is given before and after standard treatments like surgery or radiation. The main goals are to see if the pill can shrink tumors enough to avoid eye removal, reduc…

This phase 2 trial tests a new drug called roginolisib against standard treatments in 85 adults with advanced uveal melanoma, a rare eye cancer. The study aims to see if roginolisib helps people live longer and improves their quality of life. Participants are randomly assigned to…

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This study aimed to test a special vaccine made from modified melanoma cells to help the immune system fight remaining cancer in people with high-risk or low-burden melanoma. It was designed for patients with certain genetic markers and stages of melanoma. However, the study was …

This early-phase trial tests whether injecting the chemotherapy drug melphalan directly into the eye's blood vessels can shrink large uveal melanomas (eye cancers) enough to then treat them with radiation. Ten adults with tumors at least 8 mm thick will receive the chemo injectio…

This study follows 500 people diagnosed with uveal melanoma (a rare eye cancer) for five years after treatment. Participants fill out questionnaires about their physical and mental well-being, treatment side effects, and decision-making. The goal is to learn how different treatme…

This study tests whether a video-based educational program can help people who have had uveal melanoma (a rare eye cancer) better understand their disease and feel more in control. About 108 adults who completed treatment are randomly assigned to watch the video or receive usual …

This study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …

This study screens up to 1,150 people with advanced solid tumors like head and neck, cervical, or lung cancer. Researchers test blood and tumor samples to see if participants have the right genetic markers for future T-cell therapy trials. The goal is to find who might benefit fr…